Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies
about
sameAs
Risk of valvular heart disease associated with use of fenfluraminePharmacotherapies for obesity: past, current, and future therapiesDual dopamine/serotonin releasers: potential treatment agents for stimulant addictionSerotonergic drugs and valvular heart diseaseModels and strategies in the development of antiobesity drugsMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesNew and emerging drug molecules against obesity.Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityNordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine.Drug-induced valvulopathy: an update.Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapySystematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventPulmonary hypertension associated with use of phentermineSerotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat.Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.Impact of Weight Loss Surgery on Esophageal PhysiologyPostmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity.Appetite suppressants, cardiac valve disease and combination pharmacotherapyLorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Cardiovascular effects of noncardiovascular drugs.The importance of the gut microbiota after bariatric surgery.Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.Consequences of bariatric surgery on oesophageal function in health and disease.Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population.Safety and tolerability review of lorcaserin in clinical trials.Evidence for overuse of medical services around the world.Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials.The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.Toxicological findings in 889 fatally injured obese pilots involved in aviation accidents.
P2860
Q21261946-FF5C4DCF-FFC3-4602-A33B-0A261A4384C6Q21296814-65412C78-9854-4420-9B65-518A88A5EF23Q24641896-D6B06DC4-A9F6-41A7-935E-6F8E6C2CE061Q24646869-E254241B-ACA4-4603-959B-F777DB2675F6Q27002468-1325A0F9-8B3F-4A59-A6B9-3FB21FA8AC8DQ28066691-5CED3AFE-502E-4722-B447-2D6947DCB6A8Q30353872-8011A10F-6819-4EDC-B582-CDC94462B228Q33572190-BFF61D72-A3D9-420A-9B1A-30AB06FE6CE1Q33973748-1C37DF1D-37E6-4DC6-8C37-C850CC2F8B7BQ34131760-FCACBF5E-A10C-44CE-8B92-DB77C3BAB31BQ34167229-3AC3F691-5CCE-4A7A-803F-4643922A1966Q34254787-FC9D6BF9-3EF3-4104-A0E1-DB7833B4F2F4Q34373486-F706B7BB-6F73-4B00-BB9A-12CE1E549699Q34605239-3E9685E2-BFDA-4E3D-BE9C-60DC918CAD28Q34659424-0A4EC40A-9190-4E8C-8D83-B57E1991F5F3Q36544945-AFA2F0C0-09E0-43E9-A963-90ECBC8452A5Q36848440-9052A43E-B761-435B-9F89-EC594201998CQ37217297-8399AEC4-9E49-48CD-B814-2B2B6F2D352CQ37268774-B460612B-523E-4B23-85C9-A810E3F368FCQ37310802-EA1B71F7-430D-4E2F-9025-6562FD341351Q37359377-621FC13A-6A49-41C2-9D42-214F3DC570F8Q37413163-01AC60A9-06A0-4FFE-A55E-75871F93E8D7Q38038435-B48594CB-EA7D-4E23-88D4-A9D121E8811EQ38219851-BC2F4DC2-2CA0-4929-999B-D2CD296414E6Q38663160-77C7F9B0-4544-4D34-9C52-5F7625621769Q38681023-1AB760F8-373A-4EE8-8CB0-D345747F1DB0Q38954263-29F498BA-AA12-4A24-B2C2-1171D2E320B5Q39080255-4CAE0EA4-D0C4-41E9-A249-3C25F204FBE5Q39152644-38EFD6D3-CB6C-4559-AF3E-47250C5BE65FQ42364461-ECBA375D-B2D0-47AA-B7B1-82F8860DCE54Q46213450-6F7ABF6E-7D72-4C70-937F-B6C519B2F2FAQ46616131-F743D39F-E554-4579-98C5-5BD67364D638
P2860
Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effect of fenfluramine-derivat ...... lysis of observational studies
@ast
Effect of fenfluramine-derivat ...... lysis of observational studies
@en
Effect of fenfluramine-derivat ...... lysis of observational studies
@nl
type
label
Effect of fenfluramine-derivat ...... lysis of observational studies
@ast
Effect of fenfluramine-derivat ...... lysis of observational studies
@en
Effect of fenfluramine-derivat ...... lysis of observational studies
@nl
prefLabel
Effect of fenfluramine-derivat ...... lysis of observational studies
@ast
Effect of fenfluramine-derivat ...... lysis of observational studies
@en
Effect of fenfluramine-derivat ...... lysis of observational studies
@nl
P2093
P356
P1476
Effect of fenfluramine-derivat ...... lysis of observational studies
@en
P2093
James G Jollis
Molly Sachdev
Thomas Ryan
P304
P356
10.1067/MHJ.2002.126733
P407
P577
2002-12-01T00:00:00Z